Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + mitomycin c + vinblastine
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents—carboplatin, mitomycin C, and vinblastine. It is primarily used in the treatment of advanced non-small cell lung carcinoma (NSCLC), especially for patients who are inoperable or have relapsed after surgery. The regimen was developed as an alternative to the more commonly used MVP (mitomycin C, vinblastine, cisplatin) protocol by substituting carboplatin for cisplatin to reduce toxicity and facilitate outpatient administration. Carboplatin is a platinum-based compound that causes DNA crosslinking and inhibits DNA synthesis; mitomycin C acts as an alkylating agent causing DNA damage; and vinblastine disrupts microtubule formation during cell division. This combination has demonstrated similar efficacy to MVP with improved tolerability and ease of administration in outpatient settings[1][2][3].
- Other names
- MVCMVCarbo
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on carboplatin + mitomycin c + vinblastine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + mitomycin c + vinblastine.